Semaglutid was sent to starvation by Covid-19 infection

The study included approximately 17,500 patients with an indication of myocardial infarction, disease or pAVK and a BMI > 27 kg/m²but without Diabetes in 41 countries is included. This could be a problem with the GLP-1 receptor agonists Semaglutide (2.4 g subcutaneous) or Placebo discussed. In the first phase of the study, the combined endpoint of cardiovascular death, heart failure and stroke could be reduced by 20 percent (absolute risk reduction: 1.5 percent, Number Needed to Treat: 67). The duration of the follow-up period lasts 3.3 years.